MX343830B - Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. - Google Patents

Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.

Info

Publication number
MX343830B
MX343830B MX2013009274A MX2013009274A MX343830B MX 343830 B MX343830 B MX 343830B MX 2013009274 A MX2013009274 A MX 2013009274A MX 2013009274 A MX2013009274 A MX 2013009274A MX 343830 B MX343830 B MX 343830B
Authority
MX
Mexico
Prior art keywords
nucleic acid
core protein
vaccine
acid molecule
same
Prior art date
Application number
MX2013009274A
Other languages
English (en)
Other versions
MX2013009274A (es
Inventor
B Weiner David
Yan Jian
Obeng-Adjei Nyamekye
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2013009274A publication Critical patent/MX2013009274A/es
Publication of MX343830B publication Critical patent/MX343830B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Abstract

La presente invención se refiere a secuencias de ácidos nucleicos que codifican nuevas secuencias de aminoácidos de consenso de la proteína nuclear del HBV, así como construcciones/vectores genéticos y vacunas que expresan las secuencias proteínicas. También se proporcionan en la presente métodos para generar una respuesta inmunitaria contra el HBV usando las secuencias de ácidos nucleicos que se proporcionan.
MX2013009274A 2011-02-11 2012-02-13 Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. MX343830B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161442162P 2011-02-11 2011-02-11
PCT/US2012/024905 WO2012109668A1 (en) 2011-02-11 2012-02-13 Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same

Publications (2)

Publication Number Publication Date
MX2013009274A MX2013009274A (es) 2013-09-06
MX343830B true MX343830B (es) 2016-11-24

Family

ID=46638994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009274A MX343830B (es) 2011-02-11 2012-02-13 Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.

Country Status (15)

Country Link
US (3) US9403879B2 (es)
EP (2) EP3760227A1 (es)
JP (2) JP6153473B2 (es)
KR (1) KR101942372B1 (es)
CN (1) CN103442732B (es)
AU (1) AU2012214141B2 (es)
CA (1) CA2827080C (es)
EA (3) EA037377B1 (es)
ES (1) ES2806263T3 (es)
HU (1) HUE049669T2 (es)
MX (1) MX343830B (es)
PL (1) PL2672992T3 (es)
PT (1) PT2672992T (es)
WO (1) WO2012109668A1 (es)
ZA (1) ZA201306009B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037377B1 (ru) * 2011-02-11 2021-03-22 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Вакцина для индукции иммунного ответа на hbv
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EP3222677A1 (de) * 2016-03-23 2017-09-27 LANXESS Deutschland GmbH Metallazopigmente
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
EP3526332A1 (en) 2016-10-17 2019-08-21 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
CN111867624A (zh) * 2017-12-19 2020-10-30 杨森科学爱尔兰无限公司 乙型肝炎病毒(hbv)疫苗的递送方法和装置
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
AU2019210189A1 (en) 2018-01-19 2020-08-06 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
DE4090351T1 (de) 1989-03-08 1997-07-24 Health Research Inc Rekombinantes Pockenvirus-Wirtsselektionssystem
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU645489B2 (en) 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
PT681483E (pt) 1993-01-26 2005-11-30 Wyeth Corp Composicoes e metodos para distribuicao de material genetico
CA2164505A1 (en) 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides
US5407073A (en) 1993-10-01 1995-04-18 Toyo Chemical Co., Ltd. Floppy disk container
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
EP0935659A1 (en) * 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
DK1023107T3 (da) 1997-04-03 2006-12-27 Electrofect As Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
EP2428249B1 (en) 1998-07-13 2015-10-07 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
NZ512078A (en) * 1998-11-05 2004-01-30 Powderject Vaccines Inc Nucleic acid constructs comprising a hepatitis B core antigen and a cytolytic T lymphocyte antigen for genetic immunization
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
CN1599623B (zh) * 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
US7045319B2 (en) 2001-10-30 2006-05-16 Ribomed Biotechnologies, Inc. Molecular detection systems utilizing reiterative oligonucleotide synthesis
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
ES2379346T3 (es) * 2002-03-28 2012-04-25 Brenntag Biosector A/S Composiciones de vacuna combinadas de ADN/proteína
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CN100381463C (zh) 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
US20040175727A1 (en) 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
WO2004108260A2 (en) 2003-05-30 2004-12-16 Advisys, Inc. Devices and methods for biomaterial production
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
WO2005023293A1 (en) 2003-09-09 2005-03-17 Pohang University Of Science And Technology Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
WO2005116270A2 (en) 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use
AU2005287383B2 (en) * 2004-05-25 2011-09-22 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
WO2008089144A2 (en) 2007-01-12 2008-07-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Improved dna vaccination protocols
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
WO2008103380A2 (en) 2007-02-21 2008-08-28 Fox Chase Cancer Center Hepatitis b virus compositions and methods of use
KR101497728B1 (ko) 2007-05-23 2015-03-03 이노비오 파마수티컬즈, 인크. 고농도의 생물학적 활성 분자 함유 조성물 및 그 제조 방법
US8138318B2 (en) 2007-09-13 2012-03-20 Abbott Laboratories Hepatitis B pre-S2 nucleic acid
WO2009073330A2 (en) * 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
EP2234624B1 (en) 2008-01-11 2018-06-20 Inovio Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
CN107083391A (zh) * 2008-04-04 2017-08-22 宾夕法尼亚大学托管会 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
WO2010016071A2 (en) 2008-08-05 2010-02-11 Swati Subodh Identification of genomic signature for differentiating highly similar sequence variants of an organism
WO2010042751A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
US8829174B2 (en) 2008-10-29 2014-09-09 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
CN102292345B (zh) * 2008-11-17 2015-12-02 Vgx药品有限责任公司 引起对抗黄病毒的免疫应答的抗原及其应用方法
CN101502650B (zh) 2009-03-10 2011-12-28 邢益平 密码子优化的乙型肝炎核酸疫苗
WO2010127115A1 (en) 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA037377B1 (ru) 2011-02-11 2021-03-22 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Вакцина для индукции иммунного ответа на hbv
EP3266464A3 (en) 2011-02-12 2018-03-14 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
ES2726348T3 (es) 2016-08-16 2019-10-03 Guangdong Oppo Mobile Telecommunications Corp Ltd Sensor de huella dactilar y terminal que lo usa

Also Published As

Publication number Publication date
AU2012214141A1 (en) 2013-09-05
JP6153473B2 (ja) 2017-06-28
EA202092990A3 (ru) 2021-07-30
EA037377B1 (ru) 2021-03-22
EP3760227A1 (en) 2021-01-06
JP2014507146A (ja) 2014-03-27
HUE049669T2 (hu) 2020-10-28
JP2017055772A (ja) 2017-03-23
MX2013009274A (es) 2013-09-06
EA201892795A1 (ru) 2019-05-31
PT2672992T (pt) 2020-07-27
EA201391160A1 (ru) 2013-12-30
WO2012109668A1 (en) 2012-08-16
EP2672992A1 (en) 2013-12-18
EP2672992B1 (en) 2020-04-08
AU2012214141B2 (en) 2016-01-28
CA2827080C (en) 2022-09-20
PL2672992T3 (pl) 2020-11-02
US10195268B2 (en) 2019-02-05
US10695421B2 (en) 2020-06-30
EA032364B1 (ru) 2019-05-31
CA2827080A1 (en) 2012-08-16
KR20140048853A (ko) 2014-04-24
EA202092990A2 (ru) 2021-04-30
CN103442732A (zh) 2013-12-11
ZA201306009B (en) 2015-03-25
US20140023613A1 (en) 2014-01-23
US9403879B2 (en) 2016-08-02
US20160317652A1 (en) 2016-11-03
CN103442732B (zh) 2017-04-12
ES2806263T3 (es) 2021-02-17
EP2672992A4 (en) 2015-07-08
US20190151443A1 (en) 2019-05-23
KR101942372B1 (ko) 2019-04-12

Similar Documents

Publication Publication Date Title
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
MX2018008135A (es) Moleculas de acido nucleico de influenza y vacunas elaboradas a partir de las mismas.
MX2019003615A (es) Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas.
MX2018010616A (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MX2013003470A (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
IN2015DN03070A (es)
EA201990719A1 (ru) Новые промоторы
MX338052B (es) Vectores de parapoxvirus que contienen el antigeno del virus de la rabia.
PH12020500526A1 (en) Paramyxoviridae expression system

Legal Events

Date Code Title Description
FG Grant or registration